(5S,6S)-6-(3-isohexylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane | 162183-71-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (5S,6S)-6-(3-isohexylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane
• 英文别名: 3-[(5S,6S)-1-azabicyclo[3.2.1]octan-6-yl]-4-(4-methylpentylsulfanyl)-1,2,5-thiadiazole
• CAS: 162183-71-3
• 化学式: C₁₅H₂₅N₃S₂
• 分子量: 311.516
• InChiKey: NBBWYLUHFXLVBK-CHWSQXEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  82.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ethyl (1-azabicyclo[3.2.1]octan-6-yl)cyanoacetate 在 palladium on activated charcoal 二氯化二硫 、 sodium hydrogensulfide 、 氢气 、 sodium ethanolate 、 potassium carbonate 、 亚硝酸异戊酯 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、137.9 kPa 条件下， 反应 6.0h， 生成 (5S,6S)-6-(3-isohexylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane
  参考文献：
  名称：

  Muscarinic Analgesics with Potent and Selective Effects on the Gastrointestinal Tract:  Potential Application for the Treatment of Irritable Bowel Syndrome

  摘要：

  Irritable bowel syndrome (IBS) is a pathopysiolocal condition characterized by abnormal bowel habits that are frequently accompanied by abdominal pain. Current therapy based on reducing high-amplitude GI contractions with nonselective muscarinic antagonists is limited in efficacy due to typical muscarinic side effects and provides no pain relief. We have previously found potent antinociceptive agents acting through muscarinic receptors. In the present work, new 1,2,5-thiadiazole-based structures with muscarinic activity have been evaluated both for activity as analgesics in the mouse withing assay and for activity in normalizing spontaneous cluster contractions in ferret jejunum as a model of IBS in humans. (5R,6R)-exo-6-[4-[(4,4,4-Trifluorobutyl)thio]-1,2,5-thiadiazol-3-yl]-1-azabicyclo[3.2.1]octane (35, LY316108/NNC11-2192) was found to offer an exceptional profile combining analgesic potency in mouse writhing (ED(50) = 0.1 mg/kg) along with potency for normalization of GI motility (ED(50) = 0.17 mg/kg). This combination of GI and analgesic potency suggests 35 as an excellent candidate for evaluation as a potential treatment of IBS.

  DOI：

  10.1021/jm9602470

文献信息

• Method for treating anxiety using an azabicyclic oxadiazole or thiadiazole compound
  申请人：ELI LILLY AND COMPANY

  公开号：EP0709093A2

  公开（公告）日：1996-05-01

  The present invention provides the use of a compound wherein X is oxygen or sulphur; R is hydrogen, amino, halogen, -CHO, -NO₂, -OR⁴, -SR⁴, -SOR⁴, -SO₂R⁴, C₃₋₇-cycloalkyl, C₄₋₈-(cycloalkylalkyl), -Z-C₃₋₇-cycloalkyl, and -Z-C₄₋₈-(cycloalkylalkyl) wherein R⁴ is straight or branched C₁₋₁₅-alkyl, straight or branched C₂₋₁₅-alkenyl, straight or branched C₂₋₁₅-alkynyl, each of which is optionally substituted with one or more halogens, -CF₃, -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C₁₋₄-alkyl, C₁₋₄-alkoxy, -OCF₃, -CONH₂ or -CSNH₂; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C₁₋₄-alkyl, C₁₋₄-alkoxy, -OCF₃, -CONH₂ or -CSNH₂; or R is -OR⁵Y, -SR⁵Y, -OR⁵ZY, -SR⁵ZY, -O-R⁴-Z-R⁵ or -S-R⁴-Z-R⁵ wherein Z is oxygen or sulphur, R5 is straight or branched C₁₋₁₅-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched C₁₋₆-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G is selected from one of the following azabicyclic rings wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R¹ and R may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C₁₋₅-alkyl, straight or branched C₂₋₅ alkenyl, straight or branched C₂₋₅-alkynyl, straight or branched C₁₋₁₀-alkoxy, straight or branched C₁₋₅-alkyl substituted with -OH, OR⁴, halogen, -NH₂ or carboxy; R³ is H, straight or branched C₁₋₅-alkyl, straight or branched C₂₋₅-alkenyl or straight or branched C₂₋₅-alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; and --- is a single or double bond; or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of anxiety.

  本发明提供了一种化合物的用途 其中 X 是氧或硫 R 是氢、氨基、卤素、-CHO、-NO₂、-OR⁴、-SR⁴、-SOR⁴、-SO₂R⁴、C₃₋₇-环烷基、C₄₋₈-(环烷基)、-Z-C₃₋₇-环烷基、和 -Z-C₄₋₈-(环烷基)，其中 R⁴ 是直链或支链 C₁₋₁₅-烷基、直链或支链 C₂₋₁₅- 烷基、直链或支链 C₂₋₁₅-炔基，其中每个均任选被一个或多个卤素、-CF₃、-CN、苯基或苯氧基，其中苯基或苯氧基任选被卤素、-CN、C₁₋₄-烷基、C₁₋₄-烷氧基、-OCF₃、-CONH₂或-CSNH₂取代；或 R 是苯基或苄氧羰基，它们各自被卤素、-CN、C₁₋₄-烷基、C₁₋₄-烷氧基、-OCF₃、-CONH₂或-CSNH₂任选取代；或 R 是 -OR⁵Y、-SR⁵Y、-OR⁵ZY、-SR⁵ZY、-O-R⁴-Z-R⁵ 或 -S-R⁴-Z-R⁵，其中 Z 是氧或硫、R5 是直链或支链 C₁₋₁₅-炔基，Y 是含有 1 至 4 个 N、O 或 S 原子的 5 或 6 位杂环基团、O 原子或 S 原子或其组合，该杂环基团可选择在碳原子或氮原子上被直链或支链 C₁₋₆-烷基、苯基或苄基取代，或该杂环基团可选择与苯基融合；G 选自下列偶氮双环之一 其中噻二唑或噁二唑环可连接在氮杂环的任何碳原子上；R¹ 和 R 可存在于任何位置，包括噻二唑或噁二唑环的连接点，且独立地为氢、直链或支链 C₁₋₅ 烷基、直链或支链 C₂₋₅ 烯基、直链或支链 C₂₋₅ 炔基、直链或支链 C₁₋₁₀-烷氧基、被 -OH、OR⁴、卤素、-NH₂ 或羧基取代的直链或支链 C₁₋₅-烷基；R³ 是 H、直链或支链 C₁₋₅-烷基、直链或支链 C₂₋₅-烯基或直链或支链 C₂₋₅-炔基；n 是 0、1 或 2；m 是 0、1 或 2；p 是 0、1 或 2；q 是 1 或 2；以及---是单键或双键；或 其药学上可接受的盐，用于制造治疗焦虑症的药物。
• US5484794A
  申请人：——

  公开号：US5484794A

  公开（公告）日：1996-01-16
• US6271229B1
  申请人：——

  公开号：US6271229B1

  公开（公告）日：2001-08-07
• [EN] METHOD FOR TREATING ANXIETY<br/>[FR] METHODE DE TRAITEMENT DE L'ANXIETE
  申请人：ELI LILLY AND COMPANY

  公开号：WO1996013166A1

  公开（公告）日：1996-05-09

  (EN) The present invention provides a method for treating anxiety in humans using heterocyclic compounds.(FR) La présente invention offre une méthode de traitement de l'anxiété chez l'homme faisant appel à des composés hétérocycliques.
• [EN] A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS<br/>[FR] PROCEDE DE TRAITEMENT DES DYSFONCTIONNEMENTS DE LA VESSIE URINAIRE
  申请人：NOVO NORDISK A/S

  公开号：WO1996014316A1

  公开（公告）日：1996-05-17

  (EN) A method of treating urinary bladder dysfunctions in a subject in need thereof comprising administering to said subject an effective amount of a compound of formula (I) wherein X is oxygen or sulphur; and G is selected from one of the following azabicyclic rings (a) or (b) wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring.(FR) La présente invention concerne un nouveau procédé de traitement d'un sujet souffrant de dysfonctionnements de la vessie urinaire. Ce traitement consiste en l'administration au patient d'une quantité suffisante d'un composé de la formule (I). Dans cette formule, X représente oxygène ou soufre et G appartient au groupe formé par les noyaux azabicycliques représentés par les formules (a) ou (b) dans lesquelles les noyaux thiadiazole ou oxadiazole peuvent être liés à n'importe quel atome de carbone du noyau azabicyclique.